金域医学
(603882)
| 流通市值：177.41亿 | | | 总市值：178.60亿 |
| 流通股本：4.66亿 | | | 总股本：4.69亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,841,260,736.25 | 8,539,627,901.45 | 6,309,622,119.42 | 4,308,511,708.02 |
| 营业收入 | 1,841,260,736.25 | 8,539,627,901.45 | 6,309,622,119.42 | 4,308,511,708.02 |
| 二、营业总成本 | 1,739,097,569.9 | 7,635,230,948.34 | 5,575,699,748.49 | 3,676,616,414.73 |
| 营业成本 | 1,250,450,786.63 | 5,424,536,307.38 | 3,947,239,654.2 | 2,637,904,575.46 |
| 税金及附加 | 4,087,848.46 | 14,912,450.61 | 10,713,066.71 | 6,908,263.48 |
| 销售费用 | 231,582,425.82 | 1,015,089,926.04 | 737,744,888.04 | 483,669,769.16 |
| 管理费用 | 161,165,342.69 | 714,607,304.4 | 515,679,415.91 | 295,718,536.24 |
| 研发费用 | 92,123,715.26 | 467,138,909.59 | 365,465,783.65 | 254,207,470.53 |
| 财务费用 | -312,548.96 | -1,053,949.68 | -1,143,060.02 | -1,792,200.14 |
| 其中:利息费用 | 4,910,179.27 | 20,390,840.42 | 15,287,716.3 | 10,873,348.73 |
| 其中:利息收入 | 5,799,739.12 | 25,388,098.31 | 19,804,737.82 | 15,396,713.84 |
| 加:投资收益 | -2,380,675.99 | 262,966,999.25 | 262,154,829.22 | -7,126,342.24 |
| 资产处置收益 | 3,291,258.06 | 2,200,534.74 | 599,169.28 | 74,471.64 |
| 资产减值损失(新) | -242,874.19 | 519,046.86 | 546,556.16 | 290,866.77 |
| 信用减值损失(新) | -139,495,232.14 | -488,536,950.12 | -392,297,762.83 | -317,461,393.14 |
| 其他收益 | 11,643,109.08 | 78,215,490.36 | 37,489,973.05 | 28,632,108.97 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -25,021,248.83 | 759,762,074.2 | 642,415,135.81 | 336,305,005.29 |
| 加:营业外收入 | 801,067.08 | 3,782,598.02 | 2,713,184.05 | 1,839,157.74 |
| 减:营业外支出 | 2,585,760.1 | 23,256,127.9 | 17,964,545.51 | 12,215,051.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -26,805,941.85 | 740,288,544.32 | 627,163,774.35 | 325,929,111.95 |
| 减:所得税费用 | -386,528.46 | 103,380,033.29 | 60,514,085.26 | 43,693,513.02 |
| 六、净利润 | -26,419,413.39 | 636,908,511.03 | 566,649,689.09 | 282,235,598.93 |
| 持续经营净利润 | -26,419,413.39 | 636,908,511.03 | 566,649,689.09 | 282,235,598.93 |
| 归属于母公司股东的净利润 | -18,637,084.22 | 643,382,149.84 | 576,017,188.29 | 284,843,477.71 |
| 少数股东损益 | -7,782,329.17 | -6,473,638.81 | -9,367,499.2 | -2,607,878.78 |
| (一)基本每股收益 | -0.04 | 1.38 | 1.23 | 0.61 |
| (二)稀释每股收益 | -0.04 | 1.38 | 1.23 | 0.61 |
| 八、其他综合收益 | 80,537.6 | 7,990,400.18 | 15,242,181.54 | 13,272,729.33 |
| 归属于母公司股东的其他综合收益 | 80,537.6 | 7,990,400.18 | 15,242,181.54 | 13,272,729.33 |
| 九、综合收益总额 | -26,338,875.79 | 644,898,911.21 | 581,891,870.63 | 295,508,328.26 |
| 归属于母公司股东的综合收益总额 | -18,556,546.62 | 651,372,550.02 | 591,259,369.83 | 298,116,207.04 |
| 归属于少数股东的综合收益总额 | -7,782,329.17 | -6,473,638.81 | -9,367,499.2 | -2,607,878.78 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-28 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |